Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.

Timo Vesikari; Jan Hendrik Richardus; Johan Berglund; Tiina Korhonen; Carl-Erik Flodmark; Ann Lindstrand; Sven Arne Silfverdal; Vinod Bambure; Adrian Caplanusi; Ilse Dieussaert; Sumita Roy-Ghanta; David W Vaughn

doi:10.1097/INF.0000000000000709

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.

Timo Vesikari, Jan Hendrik Richardus, Johan Berglund, Tiina Korhonen, Carl-Erik Flodmark, Ann Lindstrand, Sven Arne Silfverdal, Vinod Bambure, Adrian Caplanusi, Ilse Dieussaert, Sumita Roy-Ghanta, David W Vaughn

Preventive Paediatrics

Research output: Contribution to journal › Article › peer-review

Abstract

During the influenza pandemic 2009-2010, an AS03- adjuvanted A(H1N1)pdm09 vaccine was used extensively in children 6 months of age and older, and during the 2010-2011 influenza season, the A(H1N1)pdm09 strain was included in the seasonal trivalent inactivated influenza vaccine (TIV) without adjuvant. We evaluated the immunogenicity and safety of TIV in children previously vaccinated with the AS03-adjuvanted A(H1N1)pdm09 vaccine.

Original language	English
Pages (from-to)	774-782
Journal	Pediatric Infectious Disease Journal
Volume	34
Issue number	7
DOIs	https://doi.org/10.1097/INF.0000000000000709
Publication status	Published - 2015

Subject classification (UKÄ)

Pediatrics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/INF.0000000000000709

http://www.ncbi.nlm.nih.gov/pubmed/26069949?dopt=Abstract

Fingerprint

Dive into the research topics of 'Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.'. Together they form a unique fingerprint.

Cite this

Vesikari, T., Richardus, J. H., Berglund, J., Korhonen, T., Flodmark, C.-E., Lindstrand, A., Silfverdal, S. A., Bambure, V., Caplanusi, A., Dieussaert, I., Roy-Ghanta, S., & Vaughn, D. W. (2015). Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials. Pediatric Infectious Disease Journal, 34(7), 774-782. https://doi.org/10.1097/INF.0000000000000709

@article{8dc958eb8df9435b99f43939719164df,

title = "Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.",

abstract = "During the influenza pandemic 2009-2010, an AS03- adjuvanted A(H1N1)pdm09 vaccine was used extensively in children 6 months of age and older, and during the 2010-2011 influenza season, the A(H1N1)pdm09 strain was included in the seasonal trivalent inactivated influenza vaccine (TIV) without adjuvant. We evaluated the immunogenicity and safety of TIV in children previously vaccinated with the AS03-adjuvanted A(H1N1)pdm09 vaccine.",

author = "Timo Vesikari and Richardus, {Jan Hendrik} and Johan Berglund and Tiina Korhonen and Carl-Erik Flodmark and Ann Lindstrand and Silfverdal, {Sven Arne} and Vinod Bambure and Adrian Caplanusi and Ilse Dieussaert and Sumita Roy-Ghanta and Vaughn, {David W}",

year = "2015",

doi = "10.1097/INF.0000000000000709",

language = "English",

volume = "34",

pages = "774--782",

journal = "Pediatric Infectious Disease Journal",

issn = "1532-0987",

publisher = "Lippincott Williams & Wilkins",

number = "7",

}

Vesikari, T, Richardus, JH, Berglund, J, Korhonen, T, Flodmark, C-E, Lindstrand, A, Silfverdal, SA, Bambure, V, Caplanusi, A, Dieussaert, I, Roy-Ghanta, S & Vaughn, DW 2015, 'Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.', Pediatric Infectious Disease Journal, vol. 34, no. 7, pp. 774-782. https://doi.org/10.1097/INF.0000000000000709

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials. / Vesikari, Timo; Richardus, Jan Hendrik; Berglund, Johan et al.
In: Pediatric Infectious Disease Journal, Vol. 34, No. 7, 2015, p. 774-782.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.

AU - Vesikari, Timo

AU - Richardus, Jan Hendrik

AU - Berglund, Johan

AU - Korhonen, Tiina

AU - Flodmark, Carl-Erik

AU - Lindstrand, Ann

AU - Silfverdal, Sven Arne

AU - Bambure, Vinod

AU - Caplanusi, Adrian

AU - Dieussaert, Ilse

AU - Roy-Ghanta, Sumita

AU - Vaughn, David W

PY - 2015

Y1 - 2015

N2 - During the influenza pandemic 2009-2010, an AS03- adjuvanted A(H1N1)pdm09 vaccine was used extensively in children 6 months of age and older, and during the 2010-2011 influenza season, the A(H1N1)pdm09 strain was included in the seasonal trivalent inactivated influenza vaccine (TIV) without adjuvant. We evaluated the immunogenicity and safety of TIV in children previously vaccinated with the AS03-adjuvanted A(H1N1)pdm09 vaccine.

AB - During the influenza pandemic 2009-2010, an AS03- adjuvanted A(H1N1)pdm09 vaccine was used extensively in children 6 months of age and older, and during the 2010-2011 influenza season, the A(H1N1)pdm09 strain was included in the seasonal trivalent inactivated influenza vaccine (TIV) without adjuvant. We evaluated the immunogenicity and safety of TIV in children previously vaccinated with the AS03-adjuvanted A(H1N1)pdm09 vaccine.

U2 - 10.1097/INF.0000000000000709

DO - 10.1097/INF.0000000000000709

M3 - Article

C2 - 26069949

SN - 1532-0987

VL - 34

SP - 774

EP - 782

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 7

ER -

Vesikari T, Richardus JH, Berglund J, Korhonen T, Flodmark CE, Lindstrand A et al. Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials. Pediatric Infectious Disease Journal. 2015;34(7):774-782. doi: 10.1097/INF.0000000000000709